Call us on (843) 256-3902‬‬ or email elavay@archio.io

ELAVAY 2025 BENCHMARK REPORT

The Future of Advocacy is Measurable. This Report Proves It.

The 2025 ELAVAY Advocacy Intelligence Benchmark Report analyzes how 70+ pharma, biotech, and med device companies are transforming patient engagement into strategic business impact.

Access the report through a confidential strategy briefing.

If Advocacy doesn’t drive access, it won’t survive the next budget cycle.

  • Your team builds trust, but leadership still asks for ROI.
  • You’re influencing patients, but can’t influence the product roadmap.
  • Your insights are real—but they’re not driving decisions.

The missing piece?

A system to track, benchmark, and evolve Advocacy as a core function of commercial success.

ABOUT THE REPORT

How 70+ Industry Leaders Are Reframing Advocacy as Market Intelligence

This is not a whitepaper.

It’s the most comprehensive analysis of how Advocacy teams shape market readiness, access, and trust — from preclinical to post-launch.

This is the playbook used by teams who win early, not react late.

What’s Inside:

PROOF + AUTHORITY

Already in Use by Leading Advocacy & Engagement Teams

Advocacy leaders across oncology, rare disease, immunology, and neuroscience are using the ELAVAY Benchmark Report to:

  • Shape early-stage strategy
  • Align Advocacy with Access, HEOR, and Policy
  • Strengthen the case for long-term investment
  • Become institutional stakeholders—not just storytellers

Social Proof Strip

Trusted by patient advocacy teams at…

It’s the first time our Advocacy team was seen as a driver of launch success—not just patient experience.

Director, Patient Advocacy, Top 25 Biotech

STRATEGY BRIEFING FORM

Let’s Talk About Where You Stand

To ensure alignment and context, access to the report is available through a 1:1 strategy briefing with the ELAVAY team.

The most strategic teams in pharma are already using Advocacy Intelligence.

Are you one of them?